86 related articles for article (PubMed ID: 23763533)
21. [Economic evaluation of targeted cancer therapy].
Ikeda S
Gan To Kagaku Ryoho; 2013 Aug; 40(8):967-70. PubMed ID: 23986036
[TBL] [Abstract][Full Text] [Related]
22. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Jacobs VR; Kates RE; Kantelhardt E; Vetter M; Wuerstlein R; Fischer T; Schmitt M; Jaenicke F; Untch M; Thomssen C; Harbeck N
Breast Cancer Res Treat; 2013 Apr; 138(3):839-50. PubMed ID: 23568480
[TBL] [Abstract][Full Text] [Related]
23. Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model.
Tappenden P; Chilcott J; Brennan A; Squires H; Glynne-Jones R; Tappenden J
Value Health; 2013 Jun; 16(4):542-53. PubMed ID: 23796288
[TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of four follow-up strategies after curative treatment for breast cancer: results of an RCT.
Kimman ML; Dirksen CD; Voogd AC; Falger P; Gijsen BC; Thuring M; Lenssen A; van der Ent F; Verkeyn J; Haekens C; Hupperets P; Nuytinck JK; van Riet Y; Brenninkmeijer SJ; Scheijmans LJ; Kessels A; Lambin P; Boersma LJ
Eur J Cancer; 2011 May; 47(8):1175-85. PubMed ID: 21257305
[TBL] [Abstract][Full Text] [Related]
25. The development of a value based pricing index for new drugs in metastatic colorectal cancer.
Dranitsaris G; Truter I; Lubbe MS
Eur J Cancer; 2011 Jun; 47(9):1299-304. PubMed ID: 21493060
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
[TBL] [Abstract][Full Text] [Related]
27. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
Dranitsaris G; Ortega A; Lubbe MS; Truter I
J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of proton radiation therapy in the treatment of breast cancer.
Lundkvist J; Ekman M; Ericsson SR; Isacsson U; Jönsson B; Glimelius B
Radiother Oncol; 2005 May; 75(2):179-85. PubMed ID: 15885828
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
30. Conducting an economic analysis to assess the electrocardiogram's value.
Eisenstein EL
J Electrocardiol; 2006 Apr; 39(2):241-7. PubMed ID: 16580427
[TBL] [Abstract][Full Text] [Related]
31. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
Tscheulin DK; Drevs F
Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M
Clin Breast Cancer; 2010 Aug; 10(4):267-74. PubMed ID: 20705558
[TBL] [Abstract][Full Text] [Related]
33. Patient navigation for breast and colorectal cancer in 3 community hospital settings: an economic evaluation.
Donaldson EA; Holtgrave DR; Duffin RA; Feltner F; Funderburk W; Freeman HP
Cancer; 2012 Oct; 118(19):4851-9. PubMed ID: 22392629
[TBL] [Abstract][Full Text] [Related]
34. Oral chemotherapy for colorectal cancer: some economic considerations.
Saltz L
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):29-32. PubMed ID: 11219974
[TBL] [Abstract][Full Text] [Related]
35. [Current situation and challenges in companion diagnostics development].
Nishida M
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2529-34. PubMed ID: 25596043
[TBL] [Abstract][Full Text] [Related]
36. The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine.
Li M; Yu T; Hu YF
Stat Med; 2015 Jun; 34(14):2222-34. PubMed ID: 25779099
[TBL] [Abstract][Full Text] [Related]
37. [Economic Loss of Remaining Contents in Molecular Target Drug Preparation and the Simulation for Cost Saving].
Usami E; Kimura M; Fukuoka T; Okada K; Yoshimura T
Gan To Kagaku Ryoho; 2016 Jun; 43(6):743-7. PubMed ID: 27306812
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of targeted cancer interventions: critical review and recommendations.
Elkin EB; Marshall DA; Kulin NA; Ferrusi IL; Hassett MJ; Ladabaum U; Phillips KA
Genet Med; 2011 Oct; 13(10):853-60. PubMed ID: 21637102
[TBL] [Abstract][Full Text] [Related]
39. The importance of test accuracy in economic evaluations of companion diagnostics.
San Miguel L; Hulstaert F
J Comp Eff Res; 2015 Nov; 4(6):569-77. PubMed ID: 26529499
[TBL] [Abstract][Full Text] [Related]
40. A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper.
Seo MK; Strong M
Pharmacoeconomics; 2021 Dec; 39(12):1373-1381. PubMed ID: 34414545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
